Editas Medicine, Inc. (LON: 0IFK)
London
· Delayed Price · Currency is GBP · Price in USD
1.320
+0.060 (4.76%)
Jan 23, 2025, 1:05 PM BST
Editas Medicine Revenue
Editas Medicine had revenue of $61.00K USD in the quarter ending September 30, 2024, a decrease of -98.86%. This brings the company's revenue in the last twelve months to $61.76M, up 150.95% year-over-year. In the year 2023, Editas Medicine had annual revenue of $78.12M with 296.32% growth.
Revenue (ttm)
$61.76M
Revenue Growth
+150.95%
P/S Ratio
n/a
Revenue / Employee
$233.05K
Employees
265
Market Cap
89.81M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 78.12M | 58.41M | 296.32% |
Dec 31, 2022 | 19.71M | -5.83M | -22.83% |
Dec 31, 2021 | 25.54M | -65.19M | -71.85% |
Dec 31, 2020 | 90.73M | 70.20M | 341.93% |
Dec 31, 2019 | 20.53M | -11.41M | -35.71% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
GSK plc | 31.31B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
ConvaTec Group | 1.74B |
Hikma Pharmaceuticals | 2.39B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
Editas Medicine News
- 5 days ago - Editas And Intellia: Strategic Shifts And Long-Term Investment Potential - Seeking Alpha
- 7 days ago - CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers - Seeking Alpha
- 7 days ago - Editas Medicine, Inc. (EDIT) 43rd Annual JPMorgan Healthcare Conference - (Transcript) - Seeking Alpha
- 10 days ago - Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities - GlobeNewsWire
- 17 days ago - Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 5 weeks ago - JPMorgan Downgrades Editas Medicine, Says Focus Shift Sparks Investor Caution - Benzinga
- 5 weeks ago - Editas Medicine Reshapes Future with In Vivo Focus Amid Major Workforce Cuts - GuruFocus
- 5 weeks ago - This Toll Brothers Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga